化学
激肽释放酶
丝氨酸蛋白酶
凝血酶
蛋白酵素
苯甲酰胺
丝氨酸
部分凝血活酶时间
因子十二
药理学
生物化学
凝结
蛋白酶
立体化学
酶
内科学
医学
血小板
作者
Rami A. Al‐Horani,Daniel K. Afosah,Madhusoodanan Mottamal
出处
期刊:Cardiovascular and Hematological Agents in Medicinal Chemistry
[Bentham Science Publishers]
日期:2023-07-01
卷期号:21 (2): 108-119
标识
DOI:10.2174/1871525721666221031141323
摘要
Human factor XIIa (FXIIa) is a plasma serine protease that plays a significant role in several physiological and pathological processes. Animal models have revealed an important contribution of FXIIa to thromboembolic diseases. Remarkably, animals and patients with FXII deficiency appear to have normal hemostasis. Thus, FXIIa inhibition may serve as a promising therapeutic strategy to attain safer and more effective anticoagulation. Very few small molecule inhibitors of FXIIa have been reported. We synthesized and investigated a focused library of triazol-1-yl benzamide derivatives for FXIIa inhibition.We chemically synthesized, characterized, and investigated a focused library of triazol- 1-yl benzamide derivatives for FXIIa inhibition. Using a standardized chromogenic substrate hydrolysis assay, the derivatives were evaluated for inhibiting human FXIIa. Their selectivity over other clotting factors was also evaluated using the corresponding substrate hydrolysis assays. The best inhibitor affinity to FXIIa was also determined using fluorescence spectroscopy. Effects on the clotting times (prothrombin time (PT) and activated partial thromboplastin time (APTT)) of human plasma were also studied.We identified a specific derivative (1) as the most potent inhibitor in this series. The inhibitor exhibited nanomolar binding affinity to FXIIa. It also exhibited significant selectivity against several serine proteases. It also selectively doubled the activated partial thromboplastin time of human plasma.Overall, this work puts forward inhibitor 1 as a potent and selective inhibitor of FXIIa for further development as an anticoagulant.
科研通智能强力驱动
Strongly Powered by AbleSci AI